Suramin sodium

Drug Profile

Suramin sodium

Alternative Names: Antrypol; Bayer 205; CI 1003; Germanin; Metaret; Moranyl; Suramin; Suramin hexasodium

Latest Information Update: 03 Feb 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer Austrian Academy of Sciences; Bayer; National Cancer Institute (USA); Optimum Therapeutics; Pfizer; University of California, San Diego; University of Wisconsin-Madison
  • Class Antiprotozoals; Naphthalenesulfonates
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Pervasive child development disorders
  • Discontinued Atherosclerosis; Bladder cancer; Breast cancer; Cancer pain; HIV infections; Prostate cancer; Vascular restenosis

Most Recent Events

  • 01 May 2015 Phase-I/II clinical trials in Pervasive child development disorders in USA (IV-infusion)
  • 30 Oct 2009 Discontinued - Preclinical for Vascular restenosis in Austria (unspecified route)
  • 30 Oct 2009 Discontinued - Phase-III for Prostate cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top